Effects of Aliskiren-Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients
Article first published online: 3 MAY 2012
© 2012 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 14, Issue 8, pages 522–529, August 2012
How to Cite
Kanaoka, T., Tamura, K., Ohsawa, M., Wakui, H., Maeda, A., Dejima, T., Azushima, K., Haku, S., Mitsuhashi, H., Yanagi, M., Oshikawa, J., Uneda, K., Aoki, K., Fujikawa, T., Toya, Y., Uchino, K. and Umemura, S. (2012), Effects of Aliskiren-Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients. The Journal of Clinical Hypertension, 14: 522–529. doi: 10.1111/j.1751-7176.2012.00640.x
- Issue published online: 3 AUG 2012
- Article first published online: 3 MAY 2012
- Manuscript received: December 28, 2011; Revised: February 22, 2012; Accepted: March 3, 2012
J Clin Hypertens (Greenwich). 2012;00:000–000. ©2012 Wiley Periodicals, Inc.
Aliskiren is a direct renin inhibitor that exerts its effect at the rate-limiting step of the renin-angiotensin system. This study was performed to examine the beneficial effects of aliskiren-based antihypertensive therapy on the ambulatory blood pressure (BP) profile, central hemodybamics, and arterial stiffness in untreated Japanese patients with mild to moderate hypertension. Twenty-one Japanese nondiabetic patients with untreated mild to moderate essential hypertension were initially given aliskiren once daily at 150 mg, and the dose was titrated up to 300 mg as needed. After 12 weeks of aliskiren-based therapy, the clinic, ambulatory, and central BP values as well as brachial-ankle pulse wave velocity (baPWV) were all significantly decreased compared with baseline (clinic systolic BP, 151±11 mm Hg vs 132±11 mm Hg; clinic diastolic BP, 91±13 mm Hg vs 82±9 mm Hg; 24-hour systolic BP, 144±12 mm Hg vs 133±11 mm Hg; 24-hour diastolic BP, 88±8 mm Hg vs 81±9 mm Hg; central BP, 162±16 mm Hg vs 148±14 mm Hg; baPWV, 1625±245 cm/s vs 1495±199 cm/s; P<.05). These results show that aliskiren, as a first-line regimen, improves the ambulatory BP profile and may have protective vascular effects in Japanese nondiabetic patients with untreated mild to moderate essential hypertension.